Related Experiment Video

Updated: Sep 27, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Reversal of left ventricular remodeling: role of the endothelin pathway

John R Teerlink1

  • 1University of California and the Heart Failure Clinic, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA.

Journal of Cardiac Failure
|January 30, 2003
PubMed

Insights

Neurohormone endothelin plays a key role in left ventricular remodeling. Endothelin antagonists show promise in reversing this detrimental cardiac process, offering new therapeutic avenues.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Left ventricular remodeling is a complex, time-evolving process.
  • Neurohormones significantly influence ventricular remodeling, leading to therapeutic breakthroughs.
  • Endothelin, a novel neurohormone, exhibits properties suggesting a critical role in ventricular remodeling pathophysiology.

Purpose of the Study:

  • To review the role of the endothelin pathway in left ventricular remodeling.
  • To examine evidence supporting endothelin antagonists in reversing ventricular remodeling.

Main Methods:

  • Literature review of studies investigating the endothelin pathway.
  • Analysis of preclinical and clinical data on endothelin antagonists.
  • Synthesis of current understanding of endothelin's involvement in cardiac remodeling.

Main Results:

  • The endothelin pathway is implicated in the development of left ventricular remodeling.
  • Evidence suggests endothelin antagonists can counteract and reverse remodeling processes.
  • Targeting endothelin offers a potential therapeutic strategy for heart conditions.

Conclusions:

  • The endothelin pathway is a significant contributor to left ventricular remodeling.
  • Endothelin antagonism represents a promising therapeutic approach for managing ventricular remodeling.
  • Further research into endothelin's role could yield novel treatments for cardiovascular diseases.

More Related Videos

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...